A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

This study has been completed.
Sponsor:
Information provided by:
H. Lundbeck A/S
ClinicalTrials.gov Identifier:
NCT00209950
First received: September 13, 2005
Last updated: March 29, 2007
Last verified: March 2007
  Purpose

To evaluate the safety and tolerability of gaboxadol in primary insomnia


Condition Intervention Phase
Primary Insomnia
Drug: Gaboxadol
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Open-Label Extension Study (to Study 99784) of Gaboxadol in Primary Insomnia

Further study details as provided by H. Lundbeck A/S:

Primary Outcome Measures:
  • Safety
  • Tolerability

Estimated Enrollment: 200
Study Start Date: July 2004
Study Completion Date: September 2005
Detailed Description:

To evaluate long-term safety of gaboxadol in healthy adults.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with a diagnosis of primary insomnia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00209950

Locations
Germany
Non-US study, principal location:
Regensburg, Germany
Sponsors and Collaborators
H. Lundbeck A/S
Investigators
Study Director: Please contact: Annelies van der Hammen Legters H. Lundbeck A/S
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00209950     History of Changes
Other Study ID Numbers: 10440
Study First Received: September 13, 2005
Last Updated: March 29, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by H. Lundbeck A/S:
Primary insomnia

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases
Mental Disorders
4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on July 23, 2014